Class Action Lawsuit for Investors of Applied Therapeutics
The renowned law firm Robbins Geller Rudman & Dowd LLP is extending an opportunity for investors who have experienced significant losses in Applied Therapeutics, Inc. (NASDAQ: APLT) to step forward and lead a class action lawsuit. This lawsuit pertains to securities purchases made between January 3, 2024, and December 2, 2024, during a period marked by substantial developments for Applied Therapeutics.
Understanding the Class Action Process
Investors who acquired shares of Applied Therapeutics during the defined Class Period have until February 18, 2025, to pursue a role as lead plaintiff in the associated class action case, titled Alexandru v. Applied Therapeutics, Inc.. This lawsuit alleges that both the company and certain executives failed to uphold important standards prescribed under the Securities Exchange Act of 1934.
Details of the Case
The basis of the lawsuit stems from claims that throughout the Class Period, misleading statements were made to investors. Specifically, the lawsuit mentions that Applied Therapeutics did not adhere to proper trial protocol, a situation that significantly jeopardized the acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA).
Major Allegations Against Applied Therapeutics
On January 3, 2024, it was publicly disclosed that Applied Therapeutics had submitted an NDA to the FDA for its drug, govorestat, targeting Classic Galactosemia. However, the ensuing months revealed serious concerns. For instance, on November 27, 2024, it became known that the FDA had issued a Complete Response Letter, indicating major deficiencies in the application.
Stock Impact and Investor Concerns
This revelation caused a dramatic drop in Applied Therapeutics' stock price, plunging over 80% within a few trading sessions. As if that were not enough, on December 2, 2024, further public disclosure revealed that the FDA had issued a warning regarding issues related to electronic data capture, specifically pointing to dosing errors. These escalated concerns resulted in an additional 26% decline in stock price.
The Role of the Lead Plaintiff
The implications of the Private Securities Litigation Reform Act of 1995 allow investors who are part of the Class Period to seek out appointment as lead plaintiff in this lawsuit. This designated lead plaintiff represents the collective interests of other investors and is typically selected based on their financial stake and overall suitability for this representation.
Why It Matters for Investors
Having a lead plaintiff is crucial as they steer the class action toward potential settlements or recoveries, and it provides a structured way for investors to pursue justice regarding their losses. For any investor interested in being part of this movement, acting quickly is advisable.
About Robbins Geller Rudman & Dowd LLP
Robbins Geller, one of the foremost firms representing investors involved in securities fraud cases, boasts a remarkable track record. They have achieved significant monetary recoveries for investors, totaling over $6.6 billion for those affected by securities fraud. The firm, with its extensive resources and expertise, is particularly adept at handling complex litigation.
Contact Information and Next Steps
Investors interested in discussing their position in relation to the class action lawsuit are encouraged to reach out. Robbins Geller's attorneys are available for inquiries, ensuring that each investor receives the individual attention they deserve.
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The class action lawsuit aims to gather investors who have suffered financial losses, allowing them to unite and seek redress for their grievances against Applied Therapeutics.
Who can become a lead plaintiff in this case?
Any investor who purchased Applied Therapeutics’ securities during the Class Period can apply to become the lead plaintiff, representing the interests of the entire group.
What were the key allegations against Applied Therapeutics?
The key allegations include failing to comply with trial protocols and misrepresenting the approval status of their drug applications with the FDA.
How does the stock price impact investors?
Significant drops in stock price, resulting from the disclosed issues, negatively affect investors' equity; hence, they may seek restitution through class action.
What should affected investors do next?
Affected investors should gather their information, consult with legal counsel from Robbins Geller, and consider signing up to become part of the class action lawsuit.
